Integral Diagnostics Stock Forecast, Price & News

Integral Diagnostics (ASX:IDX) Frequently Asked Questions

What stocks does MarketBeat like better than Integral Diagnostics?

Wall Street analysts have given Integral Diagnostics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Integral Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does Integral Diagnostics pay dividends? What is the dividend yield for Integral Diagnostics?

Integral Diagnostics announced a Final dividend on Monday, August 30th. Shareholders of record on Tuesday, October 5th will be paid a dividend of 0.07 per share on Tuesday, October 5th. This represents a yield of 1.47%. The ex-dividend date is Wednesday, September 1st. This is a boost from Integral Diagnostics's previous Final dividend of A$0.04.
View Integral Diagnostics' dividend history.

Is Integral Diagnostics a good dividend stock?

Integral Diagnostics pays an annual dividend of A$0.14 per share and currently has a dividend yield of 2.90%. The dividend payout ratio of Integral Diagnostics is 89.74%. Payout ratios above 75% are not desirable because they may not be sustainable.
View Integral Diagnostics' dividend history.

Who are Integral Diagnostics' key executives?

Integral Diagnostics' management team includes the following people:

• Dr. Ian Kadish M.B.A., MBBCh, MBA, CEO, MD & Director (Age 58, Pay $804.61k)
• Ms. Anne Lockwood, CFO & Chief Commercial Officer
• Dr. Jacqueline Milne MBBS, Exec. Director
• Mr. Paul McCrow, Chief Operating Officer
• Mr. Julian Gully, Chief Information Officer
• Ms. Mica Duncalfe, Chief People Officer
• Dr. Nazar Bokani, Exec. Director
• Ms. Kirsty Lally B.Com., C.A., Company Sec.

Who are some of Integral Diagnostics' key competitors?

Some companies that are related to Integral Diagnostics include Australian Clinical Labs (ACL), BARD1 Life Sciences (BD1), Biomark Diagnostics (BUX), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Signatures (GSS), Genetic Technologies (GTG), Imagin Medical (IME), Imagion Biosystems (IBX), Lifespot Health (LSH), Med BioGene (MBGNF) and Medical Imaging (MEDD).
View all of IDX's competitors.

What other stocks do shareholders of Integral Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integral Diagnostics investors own include Gevo (GEVO), Fluidigm (FLDM), EML Payments (EML), electroCore (ECOR), Dynavax Technologies (DVAX), CytoDyn (CYDY), Chimerix (CMRX), Capricor Therapeutics (CAPR), Bathurst Resources (BRL) and Athersys (ATHX).

What is Integral Diagnostics' stock symbol?

Integral Diagnostics trades on the ASX under the ticker symbol "IDX."

How much money does Integral Diagnostics make?

Integral Diagnostics has a market capitalization of $0.00 and generates $350.70 million in revenue each year.

How many employees does Integral Diagnostics have?

Integral Diagnostics employs 1,149 workers across the globe.

What is Integral Diagnostics' official website?

The official website for Integral Diagnostics is www.integraldiagnostics.com.au.

How can I contact Integral Diagnostics?

The company can be reached via phone at 61 3 5339 0704.